Gara Jalqabaatti › Saree Oljoo › Utah › Salt Lake City
Qorannoo klinikaalii Saree Oljoo Salt Lake City, UT keessatti
Qorannoo 27 Saree Oljoo f Salt Lake City fi naannoo isaa (kilomeetira 30 keessatti) hirmaatuu jiru. Qorannoo banaa eenyu akka hirmaatu fi akkamitti garee qorannoo akka quunnaman ilaali.
Takkalaa qorannoo (Ingiliffa)
Qorannoo hirmaatuu barbaadduu? Fuula kana jalatti agarsiisi — $99 guyyaa 30f →
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
Namoota walitti qabaa jiraSadarkaa 3
- Huntsman Cancer Institute, University of Utah, Salt Lake City
Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer
Namoota walitti qabaa jiraSadarkaa 3
- Clinical Trial Site, Salt Lake City
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
Namoota walitti qabaa jiraSadarkaa 3
- Utah Cancer Specialists, Salt Lake City
A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer
Namoota walitti qabaa jiraSadarkaa 2
- Huntsman Cancer Institute, Salt Lake City
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
Namoota walitti qabaa jiraSadarkaa 3
- Utah Cancer Specialists, Salt Lake City
- Huntsman Cancer Institute, University of Utah, Salt Lake City
A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer
Namoota walitti qabaa jiraSadarkaa 1/2
- University of Utah Huntsman Cancer Institute, Salt Lake City
A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
Namoota walitti qabaa jiraSadarkaa 3
- Huntsman Cancer Hospital at the University of Utah, Salt Lake City
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
Namoota walitti qabaa jiraSadarkaa 3
- University of Utah Sugarhouse Health Center, Salt Lake City
- Huntsman Cancer Institute/University of Utah, Salt Lake City
- Farmington Health Center, Farmington · Miili 15 fagaatti
A Phase 1 Study of LNCB74 in Advanced Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1
- Intermountain/LDS Hospital Ph 1 Research Program, Salt Lake City
Nurturing Exercise Routine for Greater Improvement in Zest and Energy on Enhertu
Namoota walitti qabaa jiraSadarkaa 2
- Huntsman Cancer Institute at University of Utah, Salt Lake City
Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial
Namoota walitti qabaa jiraSadarkaa 3
- Huntsman Cancer Institute/University of Utah, Salt Lake City
Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects
Namoota walitti qabaa jiraSadarkaa 3
- University of Utah - Huntsman Cancer Institute, Salt Lake City
A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1/2
- Huntsman Cancer Institute, Salt Lake City
I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
Namoota walitti qabaa jiraSadarkaa 2
- Huntsman Cancer Institute, University of Utah, Salt Lake City
A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
Namoota walitti qabaa jiraSadarkaa 3
- Huntsman Cancer Institute, Salt Lake City
Comparative Effectiveness Trial of Two Supportive Cancer Care Delivery Models for Adults With Cancer
Namoota walitti qabaa jira
- George E. Wahlen Department of Veterans Affairs Medical Center, Salt Lake City
De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)
Namoota walitti qabaa jiraSadarkaa 3
- Utah Cancer Specialists-Salt Lake City, Salt Lake City
- LDS Hospital, Salt Lake City
A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies
Namoota walitti qabaa jiraSadarkaa 1/2
- START Center for Cancer Care - Mountain Region, Salt Lake City
Feasibility Evaluation of the Muse Magnetic Resonance Guided Focused Ultrasound System
Namoota walitti qabaa jiraSadarkaa jalqabaa 1
- Huntsman Cancer Institute at University of Utah, Salt Lake City
Improving Care for Rural Patients With Solid Tumors
Namoota walitti qabaa jira
- Huntsman Cancer Institute at the University of Utah, Salt Lake City
5 vs. 9-day Course of Whole Breast Radiotherapy With Boost for Early-stage Breast Cancer
Namoota walitti qabaa jiraSadarkaa 2
- Huntsman Cancer Institute/University of Utah, Salt Lake City
SAVE Trial: SAfe Opioid Use Video Education
Namoota walitti qabaa jira
- University of Utah Huntsman Cancer Institute, Salt Lake City
Enhancing Mammography Programs for Outreach, Wellness, Education, and Resources (EMPOWER) in Underserved Populations Study
Namoota walitti qabaa jiraHojjettoota fayyaa simatamoo
- Huntsman Cancer Institute/ University of Utah, Salt Lake City
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Namoota walitti qabaa jiraQorannoo ilaalaa
- Massive Bio SYNERGY-AI site, Salt Lake City
Guided Meditation During Radiation Therapy for Breast and Gynecological Malignancies
Namoota walitti qabaa jiraSadarkaa 3
- Huntsman Cancer Institute at University of Utah, Salt Lake City
First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer
Namoota walitti qabaa jiraSadarkaa 1
- University of Utah- Huntsman Cancer Center, Salt Lake City
Community Services Navigation to Advance Health Equity in Breast Cancer Screening
Namoota walitti qabaa jira
- University of Utah Health Hospitals/Huntsman Cancer Institute Population Sciences, Salt Lake City
Qorannoo Saree Oljoo magaalota biroo keessatti
- New York City, NYQorannoo 136
- Houston, TXQorannoo 126
- Boston, MAQorannoo 112
- Nashville, TNQorannoo 81
- Los Angeles, CAQorannoo 73
- Edison, NJQorannoo 68
- St. Louis, MOQorannoo 64
- Queens, NYQorannoo 64
- Durham, NCQorannoo 64
- Chicago, ILQorannoo 59
- Philadelphia, PAQorannoo 56
- Dallas, TXQorannoo 55
Qorannoo biroo Salt Lake City keessatti
- Kansara Qara'a Non-Small CellQorannoo 31
- Saree (Gosoota Hunda)Qorannoo 27
- Kansarii ColorectalQorannoo 22
- Dhibee QaraQorannoo 21
- MelanomaQorannoo 21
- Myeloma Baay’eeQorannoo 21
- Kansara MetastatikiiQorannoo 20
- Kansarii OvariiQorannoo 19
- ObesityQorannoo 18
- Leukemia Myeloidii HamaaQorannoo 17
- Cufama OnneeQorannoo 17
- Kansarii ProstateQorannoo 15
Kanneen ClinicalTrials.gov irraa argaman, daataa 06-Onk-2026 irratti argame. Qorannoon hundi isaa kan ofii qajeelfama qoodfannaa qaba; gareen qorannoo eenyu akka hirmaatu murteessa.